Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of “Hold” by Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF) has been assigned an average rating of “Hold” from the six research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $7.50.

Several equities research analysts recently weighed in on the company. TD Cowen lowered Cardiff Oncology from a “buy” rating to a “hold” rating in a report on Monday, June 1st. HC Wainwright lowered shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a report on Monday, May 18th. Wall Street Zen cut shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Craig Hallum lowered Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday, June 3rd.

Insider Transactions at Cardiff Oncology

In other news, CEO Mani Mohindru acquired 24,703 shares of Cardiff Oncology stock in a transaction dated Thursday, June 18th. The shares were purchased at an average cost of $1.21 per share, for a total transaction of $29,890.63. Following the transaction, the chief executive officer owned 24,703 shares of the company’s stock, valued at $29,890.63. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gary W. Pace bought 30,000 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average price of $1.22 per share, with a total value of $36,600.00. Following the transaction, the director directly owned 1,356,376 shares in the company, valued at $1,654,778.72. The trade was a 2.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 8.50% of the company’s stock.

Institutional Trading of Cardiff Oncology

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Cardiff Oncology by 50.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company’s stock valued at $108,000 after purchasing an additional 11,497 shares in the last quarter. Rhumbline Advisers increased its position in shares of Cardiff Oncology by 18.8% during the first quarter. Rhumbline Advisers now owns 63,142 shares of the company’s stock valued at $198,000 after acquiring an additional 9,970 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock worth $4,723,000 after purchasing an additional 104,409 shares in the last quarter. Invesco Ltd. raised its position in Cardiff Oncology by 24.9% in the 2nd quarter. Invesco Ltd. now owns 23,795 shares of the company’s stock worth $75,000 after buying an additional 4,749 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Cardiff Oncology by 23.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock worth $69,000 after purchasing an additional 4,232 shares during the last quarter. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Price Performance

Shares of Cardiff Oncology stock traded up $0.01 on Friday, reaching $1.33. 802,290 shares of the company traded hands, compared to its average volume of 1,214,914. Cardiff Oncology has a 52 week low of $1.16 and a 52 week high of $4.55. The company has a 50 day moving average of $1.51 and a 200 day moving average of $1.86. The firm has a market capitalization of $90.93 million, a PE ratio of -1.99 and a beta of 1.44.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%.The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.09 million. As a group, analysts anticipate that Cardiff Oncology will post -0.66 earnings per share for the current year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.